Cargando…

Tau accumulation in autosomal dominant Alzheimer’s disease: a longitudinal [(18)F]flortaucipir study

Cortical tau accumulation is a key pathological event that partly defines Alzheimer’s disease (AD) onset and is associated with cognitive decline and future disease progression. However, an improved understanding of the timing and pattern of early tau deposition in AD and how this may be tracked in...

Descripción completa

Detalles Bibliográficos
Autores principales:	O’Connor, Antoinette, Cash, David M., Poole, Teresa, Markiewicz, Pawel J., Fraser, Maggie R., Malone, Ian B., Jiao, Jieqing, Weston, Philip S. J., Flores, Shaney, Hornbeck, Russ, McDade, Eric, Schöll, Michael, Gordon, Brian A., Bateman, Randall J., Benzinger, Tammie L. S., Fox, Nick C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10210376/ https://www.ncbi.nlm.nih.gov/pubmed/37231491 http://dx.doi.org/10.1186/s13195-023-01234-5

Ejemplares similares

Discovery and validation of autosomal dominant Alzheimer’s disease mutations
por: Hsu, Simon, et al.
Publicado: (2018)

Flortaucipir (tau) PET in LGI1 antibody encephalitis
por: Day, Gregory S., et al.
Publicado: (2021)

Two-period linear mixed effects models to analyze clinical trials with run-in data when the primary outcome is continuous: Applications to Alzheimer's disease
por: Wang, Guoqiao, et al.
Publicado: (2019)

Comparing cortical signatures of atrophy between late-onset and autosomal dominant Alzheimer disease
por: Dincer, Aylin, et al.
Publicado: (2020)

Single-subject grey matter network trajectories over the disease course of autosomal dominant Alzheimer’s disease
por: Vermunt, Lisa, et al.
Publicado: (2020)

Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer disease: a longitudinal study
por: Gordon, Brian A., et al.
Publicado: (2018)

Serum neurofilament light chain levels are associated with white matter integrity in autosomal dominant Alzheimer's disease
por: Schultz, Stephanie A., et al.
Publicado: (2020)

Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer’s Disease: Results from the DIAN Study Group
por: Su, Yi, et al.
Publicado: (2016)

Correction: Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer’s Disease: Results from the DIAN Study Group
por: Su, Yi, et al.
Publicado: (2016)

Relationships between big‐five personality factors and Alzheimer's disease pathology in autosomal dominant Alzheimer's disease
por: Aschenbrenner, Andrew J., et al.
Publicado: (2020)

Simultaneously evaluating the effect of baseline levels and longitudinal changes in disease biomarkers on cognition in dominantly inherited Alzheimer's disease
por: Wang, Guoqiao, et al.
Publicado: (2018)

Utilizing the Centiloid scale in cross-sectional and longitudinal PiB PET studies
por: Su, Yi, et al.
Publicado: (2018)

Decreased body mass index in the preclinical stage of autosomal dominant Alzheimer’s disease
por: Müller, Stephan, et al.
Publicado: (2017)

Ante‐ and postmortem tau in autosomal dominant and late‐onset Alzheimer’s disease
por: Chen, Charles D., et al.
Publicado: (2020)

First presentation with neuropsychiatric symptoms in autosomal dominant Alzheimer’s disease: the Dominantly Inherited Alzheimer’s Network Study
por: O'Connor, Antoinette, et al.
Publicado: (2023)

Increasing hub disruption parallels dementia severity in autosomal dominant Alzheimer disease
por: Tu, Jiaxin Cindy, et al.
Publicado: (2023)

MRI and flortaucipir relationships in Alzheimer's phenotypes are heterogeneous
por: Josephs, Keith A., et al.
Publicado: (2020)

Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study
por: Morenas-Rodríguez, Estrella, et al.
Publicado: (2022)

T1 and FLAIR signal intensities are related to tau pathology in dominantly inherited Alzheimer disease
por: Rahmani, Farzaneh, et al.
Publicado: (2023)

Parametric methods for [(18)F]flortaucipir PET
por: Golla, Sandeep SV, et al.
Publicado: (2018)

Baseline Microglial Activation Correlates With Brain Amyloidosis and Longitudinal Cognitive Decline in Alzheimer Disease
por: Wang, Qing, et al.
Publicado: (2022)

Quantitative Amyloid Imaging Using Image-Derived Arterial Input Function
por: Su, Yi, et al.
Publicado: (2015)

Importance of CSF-based Aβ clearance with age in humans increases with declining efficacy of blood-brain barrier/proteolytic pathways
por: Elbert, Donald L., et al.
Publicado: (2022)

Utility of perfusion PET measures to assess neuronal injury in Alzheimer's disease
por: Joseph-Mathurin, Nelly, et al.
Publicado: (2018)

(18)F-Flortaucipir in TDP-43 associated frontotemporal dementia
por: Smith, R., et al.
Publicado: (2019)

CSF Tau phosphorylation at Thr205 is associated with loss of white matter integrity in autosomal dominant Alzheimer disease
por: Strain, Jeremy F., et al.
Publicado: (2022)

Detection of tau in Gerstmann-Sträussler-Scheinker disease (PRNP F198S) by [(18)F]Flortaucipir PET
por: Risacher, Shannon L., et al.
Publicado: (2018)

The informed road map to prevention of Alzheimer Disease: A call to arms
por: McDade, Eric, et al.
Publicado: (2021)

Head-to-head comparison of tau positron emission tomography tracers [(18)F]flortaucipir and [(18)F]RO948
por: Smith, Ruben, et al.
Publicado: (2019)

Brain volume and flortaucipir analysis of progressive supranuclear palsy clinical variants
por: Whitwell, Jennifer L., et al.
Publicado: (2019)

Flortaucipir tau PET imaging in semantic variant primary progressive aphasia
por: Makaretz, Sara J, et al.
Publicado: (2018)

Cerebrospinal fluid proteomics define the natural history of autosomal dominant Alzheimer’s disease
por: Johnson, Erik C. B., et al.
Publicado: (2023)

Predicting sporadic Alzheimer’s disease progression via inherited Alzheimer’s disease-informed machine-learning
por: Franzmeier, Nicolai, et al.
Publicado: (2020)

Reduced acquisition time PET pharmacokinetic modelling using simultaneous ASL–MRI: proof of concept
por: Scott, Catherine J, et al.
Publicado: (2018)

Evaluation of a visual interpretation method for tau‐PET with (18)F‐flortaucipir
por: Sonni, Ida, et al.
Publicado: (2020)

The Role of 18F-Flortaucipir (AV-1451) in the Diagnosis of Neurodegenerative Disorders
por: Roy, Saswata, et al.
Publicado: (2021)

Selecting software pipelines for change in flortaucipir SUVR: Balancing repeatability and group separation
por: Schwarz, Christopher G., et al.
Publicado: (2021)

(18)F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes
por: Tsai, Richard M., et al.
Publicado: (2019)

Data-driven models of dominantly-inherited Alzheimer’s disease progression
por: Oxtoby, Neil P, et al.
Publicado: (2018)

Association of the top 20 Alzheimer's disease risk genes with [(18)F]flortaucipir PET
por: Stage, Eddie, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1v508m5t0jdvu5bgkl501779tv